chondroitin-sulfates and Budd-Chiari-Syndrome

chondroitin-sulfates has been researched along with Budd-Chiari-Syndrome* in 1 studies

Other Studies

1 other study(ies) available for chondroitin-sulfates and Budd-Chiari-Syndrome

Article	Year
[Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia]. Annales francaises d'anesthesie et de reanimation, 2004, Volume: 23, Issue:1 We report a case of Budd-Chiari syndrome revealing a polycythemia vera and complicated by heparin-induced thrombocytopenia. A surgical porto-caval shunt was inserted with danaparoid as anticoagulant during the peri-operative period. The doses of danaparoid were as follows: a continuous intravenous infusion of 200 U/h with a target between 0.5 et 0.8 U/ml antifactor Xa activity during the preoperative period, followed by 100 U/h with a target of 0.3 U/ml during the peroperative period; an increase in doses of danaparoid to 150 and 200 U/h with a target above 0.5 U/ml was used during the postoperative period. This case report is a rare situation of hypercoagulable state, in a surgical context, treated with danaparoid. Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Factor Xa Inhibitors; Female; Heparin; Heparitin Sulfate; Humans; Infusions, Intravenous; Platelet Aggregation; Thrombocytopenia	2004

Article

Year

[Peri-operative anticoagulation with danaparoid for a patient with Budd-Chiari syndrome and heparin-induced thrombocytopenia].

Annales francaises d'anesthesie et de reanimation, 2004, Volume: 23, Issue:1

We report a case of Budd-Chiari syndrome revealing a polycythemia vera and complicated by heparin-induced thrombocytopenia. A surgical porto-caval shunt was inserted with danaparoid as anticoagulant during the peri-operative period. The doses of danaparoid were as follows: a continuous intravenous infusion of 200 U/h with a target between 0.5 et 0.8 U/ml antifactor Xa activity during the preoperative period, followed by 100 U/h with a target of 0.3 U/ml during the peroperative period; an increase in doses of danaparoid to 150 and 200 U/h with a target above 0.5 U/ml was used during the postoperative period. This case report is a rare situation of hypercoagulable state, in a surgical context, treated with danaparoid.

Topics: Adult; Anticoagulants; Budd-Chiari Syndrome; Chondroitin Sulfates; Dermatan Sulfate; Drug Combinations; Factor Xa Inhibitors; Female; Heparin; Heparitin Sulfate; Humans; Infusions, Intravenous; Platelet Aggregation; Thrombocytopenia

2004